Clinical Trials - September 6, 2017
Promising results from Symphogen
Last Friday, Symphogen presents results from a randomized Phase 2 study with Sym004, a mAb mixture targeting EGFR. Their report ad results has been selected for oral presentation on 11 September 2017 at the European Society for Medical Oncology (ESMO) 2017 Congress, taking place from 8-12 September 2017, in Madrid, Spain. “Data from the large […]
Uncategorized - June 1, 2015
Symphogen Publishes 3 Papers
Symphogen, a biopharmaceutical company developing recombinant antibody mixtures, published two papers with new clinical data for its lead anti-EGFR antibody mixture, Sym004, in the journals Cancer Discovery and in Cancer Chemotherapy and Pharmacology. In addition, a paper in Clinical Cancer Research described preclinical findings relating to the company’s pan-HER product candidate, Sym013, a mixture of six antibodies targeting each of […]
Acquisition - February 5, 2015
Symphogen, Merck End Pact
Danish biotech company Symphogen once again has its lead asset in its portfolio, experimental cancer drug Sym004, three years after it partnered with Merck on a $625 million deal for its development. The two companies said recently that they have ended their collaboration, with Symphogen saying it hopes to now turn itself into a standalone […]
